Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM85 for prevention of severe lower respiratory illness in frontline healthcare workers
ACTRN12620000473965Phase 3Completed
- Sponsor
- The University of Queensland
- Start
- Aug 2020
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of OM-85 in coronavirus disease 2019 (COVID-19), acute respiratory illness (ARI) and pulmonary infection (2 arms), sponsored by The University of Queensland. Primary endpoint: Proportion of healthcare workers contracting an acute respiratory illness necessitating workforce removal. Started Aug 2020; status: completed.
02
Drugs
OM-85
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory illness (ARI)pulmonary infection
Beyond the preview
Go deeper on ACTRN12620000473965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000473965.